Jamie L Huizinga1, Elizabeth E Stanley1, James K Sullivan1, Shuang Song1, David J Hunter2, A David Paltiel3, Tuhina Neogi4, Robert R Edwards5, Jeffrey N Katz6, Elena Losina7. 1. Brigham and Women's Hospital, Boston, Massachusetts. 2. University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia. 3. Yale School of Public Health, New Haven, Connecticut. 4. Boston University School of Medicine, Boston, Massachusetts. 5. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 6. Brigham and Women's Hospital, Harvard Medical School, and Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 7. Brigham and Women's Hospital, Harvard Medical School, and Boston University School of Public Health, Boston, Massachusetts.
Abstract
OBJECTIVE: Symptomatic knee osteoarthritis (SKOA) is a chronic, disabling condition, requiring long-term pain management; over 800,000 SKOA patients in the US use opioids on a prolonged basis. We aimed to characterize the societal economic burden of opioid use in this population. METHODS: We used the Osteoarthritis Policy Model, a validated computer simulation of SKOA, to estimate the opioid-related lifetime and annual cost generated by the US SKOA population. We included direct medical, lost productivity, criminal justice, and diversion costs. We modeled the SKOA cohort with a mean ± SD age of 54 ± 14 years and Western Ontario and McMaster Universities Osteoarthritis Index pain score of 29 ± 17 (0-100, 100 = worst). We estimated annual costs of strong ($1,381) and weak ($671) opioid regimens using Medicare fee schedules, Red Book, the Federal Supply Schedule, and published literature. The annual lost productivity and criminal justice costs of opioid use disorder (OUD), obtained from published literature, were $11,387 and $4,264, per-person, respectively. The 2015-2016 Medicare Current Beneficiary Survey provided OUD prevalence. We conducted sensitivity analyses to examine the robustness of our estimates to uncertainty in input parameters. RESULTS: Assuming 5.1% prevalence of prolonged strong opioid use, the total lifetime opioid-related cost generated by the US SKOA population was estimated at $14.0 billion, of which only $7.45 billion (53%) were direct medical costs. CONCLUSION: Lost productivity, diversion, and criminal justice costs comprise approximately half of opioid-related costs generated by the US SKOA population. Reducing prolonged opioid use may lead to a meaningful reduction in societal costs that can be used for other public health causes.
OBJECTIVE: Symptomatic knee osteoarthritis (SKOA) is a chronic, disabling condition, requiring long-term pain management; over 800,000 SKOA patients in the US use opioids on a prolonged basis. We aimed to characterize the societal economic burden of opioid use in this population. METHODS: We used the Osteoarthritis Policy Model, a validated computer simulation of SKOA, to estimate the opioid-related lifetime and annual cost generated by the US SKOA population. We included direct medical, lost productivity, criminal justice, and diversion costs. We modeled the SKOA cohort with a mean ± SD age of 54 ± 14 years and Western Ontario and McMaster Universities Osteoarthritis Index pain score of 29 ± 17 (0-100, 100 = worst). We estimated annual costs of strong ($1,381) and weak ($671) opioid regimens using Medicare fee schedules, Red Book, the Federal Supply Schedule, and published literature. The annual lost productivity and criminal justice costs of opioid use disorder (OUD), obtained from published literature, were $11,387 and $4,264, per-person, respectively. The 2015-2016 Medicare Current Beneficiary Survey provided OUD prevalence. We conducted sensitivity analyses to examine the robustness of our estimates to uncertainty in input parameters. RESULTS: Assuming 5.1% prevalence of prolonged strong opioid use, the total lifetime opioid-related cost generated by the US SKOA population was estimated at $14.0 billion, of which only $7.45 billion (53%) were direct medical costs. CONCLUSION: Lost productivity, diversion, and criminal justice costs comprise approximately half of opioid-related costs generated by the US SKOA population. Reducing prolonged opioid use may lead to a meaningful reduction in societal costs that can be used for other public health causes.
Authors: R R Bannuru; M C Osani; E E Vaysbrot; N K Arden; K Bennell; S M A Bierma-Zeinstra; V B Kraus; L S Lohmander; J H Abbott; M Bhandari; F J Blanco; R Espinosa; I K Haugen; J Lin; L A Mandl; E Moilanen; N Nakamura; L Snyder-Mackler; T Trojian; M Underwood; T E McAlindon Journal: Osteoarthritis Cartilage Date: 2019-07-03 Impact factor: 6.576
Authors: David E DeMik; Nicholas A Bedard; S Blake Dowdle; Robert A Burnett; Michael A McHugh; John J Callaghan Journal: J Arthroplasty Date: 2017-07-25 Impact factor: 4.757
Authors: Savannah R Smith; Jeffrey N Katz; Jamie E Collins; Daniel H Solomon; Joanne M Jordan; Lisa G Suter; Edward H Yelin; A David Paltiel; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2016-12-31 Impact factor: 4.794
Authors: Sharon L Kolasinski; Tuhina Neogi; Marc C Hochberg; Carol Oatis; Gordon Guyatt; Joel Block; Leigh Callahan; Cindy Copenhaver; Carole Dodge; David Felson; Kathleen Gellar; William F Harvey; Gillian Hawker; Edward Herzig; C Kent Kwoh; Amanda E Nelson; Jonathan Samuels; Carla Scanzello; Daniel White; Barton Wise; Roy D Altman; Dana DiRenzo; Joann Fontanarosa; Gina Giradi; Mariko Ishimori; Devyani Misra; Amit Aakash Shah; Anna K Shmagel; Louise M Thoma; Marat Turgunbaev; Amy S Turner; James Reston Journal: Arthritis Rheumatol Date: 2020-01-06 Impact factor: 10.995
Authors: Tonia L Vincent; Tamara Alliston; Mohit Kapoor; Richard F Loeser; Linda Troeberg; Christopher B Little Journal: Clin Geriatr Med Date: 2022-05 Impact factor: 3.529
Authors: Louis P Garrison; Patricia Schepman; Andrew G Bushmakin; Rebecca L Robinson; Leslie Tive; Jerry Hall; Mendwas Dzingina; James Jackson; Mia Berry; Joseph C Cappelleri; Stuart Silverman Journal: Qual Life Res Date: 2021-07-05 Impact factor: 4.147